For the Inventor, By the Inventor

Enter assignee name

Incline Village, NV, United States of America

Pdl Biopharma, Inc.

USPTO Granted Patents = 20

CIPO Patents = 1

EPO Patents = 4

Trademarks = 1

Forward Citations = 495

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Naoya Tsurushita (7 out of 49 patents)

Paul Robert Hinton (6 out of 21 patents)

Maximiliano Vasquez (5 out of 68 patents)

4. J Yun Tso (4 out of 48 patents)

5. Vanitha Ramakrishnan (4 out of 20 patents)

6. Vinay Bhaskar (3 out of 38 patents)

7. David Powers (3 out of 24 patents)

8. Debbie Law (3 out of 10 patents)

9. Kurt C Gish (2 out of 27 patents)

10. Jonathan K Leland (2 out of 58 patents)

11. Nicholas F Landolfi (2 out of 19 patents)

12. Dale E Johnson (2 out of 8 patents)

13. Ursula Jeffry (2 out of 7 patents)

14. David H Mack (2 out of 24 patents)

15. Paul Hu (1 out of 4 patents)

20 patents: Sort by Forward Citations

1. 10716887 - Filtration module (2020-07-21),

2. 10401368 - Antibodies and methods for the detection of cell death (2019-09-03),

3. 10125385 - Electrochemiluminescence (ECL) detection reagents and related methods for measuring enzyme activity (2018-11-13),

4. 10029041 - Filtration module (2018-07-24),

5. 7846435 - Humanized antibodies that recognize Verotoxin II and cell line producing same (2010-12-07),

6. 7435589 - Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer (2008-10-14),

7. 7399469 - Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer (2008-07-15),

8. 7381803 - Humanized antibodies against CD3 (2008-06-03),

9. 7365168 - Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis (2008-04-29),

10. 7361740 - Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis (2008-04-22),

11. 7288248 - Antibodies against cancer antigen TMEFF2 and uses thereof (2007-10-30),

12. 7285268 - Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis (2007-10-23),

13. 7276589 - Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis (2007-10-02),

14. 7276372 - Antibodies against GPR64 and uses thereof (2007-10-02),

15. 7223393 - Amphiregulin antibodies and their use to treat cancer and psoriasis (2007-05-29),

PDL BioPharma, Inc. is a healthcare company dedicated to improving the lives of patients by acquiring and managing a portfolio of companies and assets in the biotechnology and pharmaceutical sectors. With a focus on maximizing value for shareholders, PDL BioPharma actively pursues investments in innovative therapies and technologies. Through strategic collaborations and partnerships, the company aims to bring breakthrough treatments to market and drive positive outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

20 Patents

#6 in Incline Village, NV

#117 in Nevada

#15,886 in US

#30,351 in the World

Incline Village, NV, United States of America

Pdl Biopharma, Inc.

Forward Citations = 495

41 inventors:

Naoya Tsurushita (7 out of 49 patents)

Paul Robert Hinton (6 out of 21 patents)

Maximiliano Vasquez (5 out of 68 patents)

4. J Yun Tso (4 out of 48 patents)

5. Vanitha Ramakrishnan (4 out of 20 patents)

Please report any incorrect information to support@idiyas.com

Loading…